Amgen’s statement on the General Authority for Competition’s (GAC) announcement.
On February 7, the General Authority for Competition (GAC) in Saudi Arabia released a statement regarding an ongoing legal case which Amgen Europe GmbH is in the process of appealing. While we respect the GAC, we strongly disagree with its statement and find it premature to comment on a case which has not been concluded.
Amgen works every day to deliver the best possible therapies to save and improve patient’s lives and accelerate biopharmaceutical innovation in Saudi Arabia. Compliance is the bedrock of our business and we remain vigilant to conduct business fairly and in the best interest of patients.
Recently, as part of this commitment in Saudi Arabia, Amgen established a local legal entity, launched six innovative medicines for local patients, and invested in multiple local partnerships to support the Saudi 2030 vision to diversify from its core sectors. We are actively working to build a strong and sustainable presence in Saudi Arabia by providing valued-based programs for patients and healthcare providers as well as increased local hires and training.